Can CA 19-9 predict inferior surgical and pathological outcomes for resectable pancreatic cancer?

被引：0
|
作者：
Jabbal, Iktej Singh
Nagarajan, Arun
Roy, Mayank
Rivera, Carlos
Yaghi, Marita
Liang, Hong
Nguyen, Timmy Q.
George, Tiffany L.
Nahleh, Zeina A.
Simpfendorfer, Conrad H.
机构：
[1] Cleveland Clin Florida, Weston, FL USA
[2] Cleveland Clin, Weston, FL USA
[3] Cleveland Clin Florida, Coral Springs, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16228
引用
收藏
页码：E16288 / E16288
页数：1
相关论文
共 50 条
  • [31] Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
    Halm, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (35) : 5610 - 5610
  • [32] Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
    Ferrone, Cristina R.
    Finkelstein, Dianne M.
    Thayer, Sarah P.
    Muzikansky, Alona
    Fernandez-del Castillo, Carlos
    Warshaw, Andrew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2897 - 2902
  • [33] Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma
    Shishir K. Maithel
    Stephen Maloney
    Corrine Winston
    Mithat Gönen
    Michael I. D’Angelica
    Ronald P. DeMatteo
    William R. Jarnagin
    Murray F. Brennan
    Peter J. Allen
    Annals of Surgical Oncology, 2008, 15 : 3512 - 3520
  • [34] Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma
    Maithel, Shishir K.
    Maloney, Stephen
    Winston, Corrine
    Goenen, Mithat
    D'Angelica, Michael I.
    DeMatteo, Ronald P.
    Jarnagin, William R.
    Brennan, Murray F.
    Allen, Peter J.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (12) : 3512 - 3520
  • [35] CA 19-9 and pancreatic carcinoma, a revival?
    Ducreux, Michel
    Boige, Valerie
    Malka, David
    ONKOLOGIE, 2007, 30 (1-2): : 12 - 13
  • [36] The Association Between Elevated CA 19-9 and Recurrence, Site of Recurrence, and Overall Survival in Upfront Resectable Pancreatic Cancer
    Powers, B.
    Kim, J. K.
    Deperalta, D. K.
    Ogami, T.
    Pimiento, J.
    Hodul, P. J.
    Malafa, M. P.
    Fleming, J.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S145 - S146
  • [37] Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
    Katz, Matthew H. G.
    Varadhachary, Gauri R.
    Fleming, Jason B.
    Wolff, Robert A.
    Lee, Jeffrey E.
    Pisters, Peter W. T.
    Vauthey, Jean-Nicolas
    Abdalla, Eddie K.
    Sun, Charlotte C.
    Wang, Huamin
    Crane, Christopher H.
    Lee, Jeffrey H.
    Tamm, Eric P.
    Abbruzzese, James L.
    Evans, Douglas B.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (07) : 1794 - 1801
  • [38] Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
    Matthew H. G. Katz
    Gauri R. Varadhachary
    Jason B. Fleming
    Robert A. Wolff
    Jeffrey E. Lee
    Peter W. T. Pisters
    Jean-Nicolas Vauthey
    Eddie K. Abdalla
    Charlotte C. Sun
    Huamin Wang
    Christopher H. Crane
    Jeffrey H. Lee
    Eric P. Tamm
    James L. Abbruzzese
    Douglas B. Evans
    Annals of Surgical Oncology, 2010, 17 : 1794 - 1801
  • [39] CA 19-9 IN PANCREATIC CANCER: RETROSPECTIVE EVALUATION OF 20 YEARS
    Molina, V.
    Visa, L.
    Conill, C.
    Navarro, S.
    Escudero, J. M.
    Auge, J. M.
    Filella, X.
    Fernandez Cruz, L.
    Ferrer, J.
    Molina, R.
    ANTICANCER RESEARCH, 2011, 31 (05) : 1996 - 1996
  • [40] Prognostic value of CA 19-9 serum course in pancreatic cancer
    Safi, F
    Schlosser, W
    Falkenreck, S
    Beger, HG
    HEPATO-GASTROENTEROLOGY, 1998, 45 (19) : 253 - 259
12345